Trial site
Istituti Clinici Scientifici Maugeri S.p.A. Societa' Benefit In Forma Abbreviata Istituti Clinici Scientifici Maugeri S.p.A. Sb O Anche Ics Maugeri S.p.A. Sb O Maugeri S.p.A. Sb
Pavia, 27100, ItalyNot linked to an institution yet
- 18running trials
- 1closed trial
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 27 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Recruiting8 trials
- Active, not recruiting5 trials
- Not yet recruiting5 trials
- Completed1 trial
- Suspended1 trial
- Lead sponsor
- AstraZeneca2 trials
- Immunovant Sciences GmbH2 trials
- Novartis Pharmaceuticals2 trials
- Azienda Ospedaliera Ordine Mauriziano Di Torino1 trial
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia1 trial
- and 12 more
Running trials
Not yet recruiting
Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
2026-526113-28-00· Phase 4· Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
2024-519638-22-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source
Active, not recruiting
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899· Phase 2· Cardurion Pharmaceuticals, Inc.· Source
Not yet recruiting
Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial
2022-503119-40-00· Phase 3· Azienda Ospedaliera Ordine Mauriziano Di Torino· Source
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275· Phase 2/3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· Phase 3· Takeda· Source
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· Phase 3· AstraZeneca· Source
Active, not recruiting
Atacicept in Subjects With IgA Nephropathy
NCT04716231· Phase 3· Vera Therapeutics, Inc.· Source
Not yet recruiting
Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy.
2024-518892-72-00· Phase 2· Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia· Source
Recruiting
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
NCT04662723· Phase 4· Fondazione Schena· Source
Active, not recruiting
Atrasentan in Patients With IgA Nephropathy
NCT04573478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219· Phase 3· Exelixis· Source
Active, not recruiting
MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC
NCT03975114· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error